Incidence of Metabolic Diseases is rising globally and developing new treatments is essential to address the unmet medical need. At Evotec our expertise in metabolic disorders has grown over the past 20 years, working on projects related to obesity, diabetes, liver diseases (MASLD/MASH), kidney diseases, and muscle related disorders. Our expert teams of dedicated and experienced drug discovery scientists dive deep into the science of your targets and therapeutic focus, to design and execute complete multi-modality drug discovery projects ranging from target validation to preclinical candidate development stages.
In Vitro
We offer a comprehensive array of translational in vitro models, assays and readouts covering all major metabolic tissues such as pancreatic islets, adipose tissue, skeletal muscle and liver. We work with primary or immortalized human and mouse cells, including iPSC-derived cells. We have also established more complex in vitro or ex-vivo models: advanced 2D cellular models, 3D tissue spheroids and organoids, coculture models, precision cut tissue slices, and tissue explants. Many of our functional and disease-relevant in vitro assays and models are compatible with high throughput screening and testing.
In Vivo
Our in vivo department also offers a wide variety of validated animal models for Metabolic diseases ranging from genetic, surgery-, compound- or diet-induced disease models.
Human Datasets
Evotec’s growing Molecular Patient Database (E.MPD) was enriched with a large obesity and metabolic disease patient cohort in 2024. With multiple tissues available and planned multi-omic analyses, we are aiming to get a deep understanding of disease drivers and mechanisms. These unique datasets will support therapeutic target and biomarker identification, and patient stratification approaches.
